The harness for n‑of‑1 medicine
If you run the protocol properly, the evidence falls out of care
A first study starts from care run on iksa, where every draw keeps its date and source and every plan item its note.
On this page7
What does a first study look like?
It is built on patients already in care at clinics on iksa, the harness for n‑of‑1 medicine, each on a protocol their doctor wrote and has changed over the years.
What falls out of that care is the record the study reads, built to hold each protocol, each marker against where that patient started, and the doctor’s decisions in the dated notes where they were written.
Read across patients, those draws and decisions show how markers moved in people like these on an intervention, and what their doctors did next. Drawn below are four patients in different protocols and the five kinds of marker these clinics read.
Illustrative
What’s the indication, and what is the endpoint?
The indication is yours to name, a condition a regulator already recognizes, and the fit follows from who is already on the therapy.
What a patient is already on can screen them out of a new candidate’s study, while here it is what the study reads, with their other protocols read beside it, so the fit is a therapy in these clinics’ hands today, or a new use for it.
The endpoint starts from what care already measures. For a longevity therapy that means reading function as VO2 max and grip strength, with lean mass on DEXA and the conventional markers beside them, and whatever else your question needs is written into the study with the clinic.
The timing of draws belongs to each patient, closer together while a dose is moving and further apart once it settles. So a first study reads each draw and change on its date and models why each draw came when it did, because draws that come sooner when something moved bias a naive average.
Whether a marker is reliable and moves under a real intervention, in the same people across repeated draws, is the question this record is built toward answering.
The field put the epigenetic clocks to that question this year, pooling 51 before-and-after intervention studies, where drugs moved them more than lifestyle did, while supplements and procedures weren’t significant as categories and no clinically important difference has been defined (Nature Medicine, August 2026 (opens in a new tab)).
Within one person, on a reliability scale where 1 means every repeat matches, clocks scored mostly above 0.9 on the same sample run twice but about 0.4 to 0.7, the range of some routine labs, on draws hours to days apart (Aging Cell, August 2026 (opens in a new tab)), and eleven more clocks run on published single-clock results corroborated none of them (Aging Cell, October 2026 (opens in a new tab)).
So a clock is context, trended on one fixed clock while function and the conventional markers drive the doctor’s decisions, and a real change in one patient’s marker is one larger than that marker’s own variation across repeat draws.
What exactly was given, and from when?
A first study starts from what the doctor planned, so the record is built to name the therapy, the markers monitored and the targets on each protocol, with its dates, and a patient on several at once reads as one person with each protocol named.
The note behind the plan opens with its author, date and type, so a change can be read where the doctor wrote it.
What each patient actually received is the next step, read from the plan and what was billed as given, both already on the record.
The source behind those lines and who did what and when are the next questions from your evidence lead or a journal’s reviewer, and the page for biotech and life sciences answers both under Would the data hold up?
What does a first study give you, and where does the time go?
What you get is one question read across patients on the therapy, each from the baseline drawn before they started it, and what comes out tells you what to test prospectively next.
A first study opens on baselines already drawn, because the labs, notes and plans behind them are on the record with their dates, so the study’s time goes to the follow-up your question still needs.
How does a first study start?
It starts with your question, and we design one study with the clinics that run it.
Each patient’s doctor then runs that patient’s protocol as care, changing it when the numbers call for it.
The question
The protocol, run properly
The evidence from care
Bring the one question your next study has to answer, and we’ll start from there.
Start a study conversationWhat kind of research is this?
It’s the real-world evidence longevity clinics can produce from the care they already give: observational research designed with partner clinics, because each patient’s doctor writes the plan and the study reads the record those clinics already keep.
A preprint from inside the field says longevity medicine “still lacks the quality infrastructure that mature health disciplines take for granted” (Preprints.org, September 2026 (opens in a new tab)), which is the gap a study read from care is designed to close.
A study would run on de-identified data, with each patient’s consent, under ethics review and the terms written into each clinic’s agreement.
Who is this for?
This is for the clinician who wants to publish and the researcher looking for dense data on people under real interventions, and for the head of clinical development deciding where the next study runs and the developer of a therapy clinics already deliver, with the evidence lead beside them, who has to defend a data source for one specific question.
If you came here first from the sponsor’s side, the page For biotech and life sciences sets out what these clinics give a study, and the conversation starts with your question from either page.
Bring us your question
Tell us what you want to learn and publish and which patients it is about, and we’ll come straight back on which clinics could run it and what a first study there reads.